The Journal of Urology Vol. 203 (2020): May
Most Comprehensive and Affordable Self-study CME Product!
Make the most of your Journal of Urology® Subscription
Developed by a team of educators, academicians, and clinicians, this valuable home study activity will enhance your knowledge of urology and improve performance as well as patient care at your convenience. For just $2.50 per credit, the Home Study program is designed to provide urologists and residents affordable access to the most recent developments and techniques in urology while reading The Journal®.
Each month includes 5 clinically-relevant, selected articles with a corresponding online test for each of the 12 issues of The Journal®.
The American Urological Association designates this enduring material for a maximum of 24 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This Home Study Course is available only to subscribers of The Journal of Urology® and includes volumes 203 and 204.
The 2020 posttests will be posted online as they become available each month.
Target Audience
- Practicing Urologists
- American Board of Urology (ABU) candidates
- Residents
Learning Objectives
After completing each lesson, the participants should be able to:
- Assess their knowledge of urology
- Demonstrate an increased knowledge base of urology
- Apply the increased knowledge to improve quality of patient care
Disclosures
(Individuals in control of the content. All individuals with their respective disclosures listed in this document are planners. Individual authors’ disclosures are located with their articles in each issue of The Journal of Urology®.)
Planner Disclosures
Victor Nitti, MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial
Brant Inman, MD, MS: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Genentech, Inc.: Scientific Study or Trial; Combat Medical: Consultant or Advisor; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor
The Journal of Urology® Editorial Board
Name | Company | Role |
Anthony Atala, MD | Plureon Inc | Leadership Position |
Duane D. Baldwin, MD | Cook Urological, Inc. | Meeting Participant or Lecturer |
Olympus Corporation | Consultant or Advisor | |
Bard Medical Divison | Consultant or Advisor | |
DARRT | Leadership Position | |
StepLite | Leadership Position | |
Pfizer | Investment Interest | |
Daniel Ari Barocas, MD | Astra Zeneca | Meeting Participant or Lecturer |
Tolmar | Consultant or Advisor | |
Peter Colin Black, MD | GenomeDx Biosciences Inc | Consultant or Advisor, Scientific Study or Trial |
Janssen | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
Astellas | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
Amgen | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
Sitka | Consultant or Advisor | |
AbbVie | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
Biosyent | Consultant or Advisor | |
Bristol Myers Squibb | Consultant or Advisor | |
PLOS ONE | Health Publishing | |
BMC Urology | Health Publishing | |
Merck | Consultant or Advisor | |
iProgen | Scientific Study or Trial | |
Bayer | Consultant or Advisor | |
New B Innovation | Scientific Study or Trial | |
RedLeaf Medical | Meeting Participant or Lecturer | |
Biocancell | Consultant or Advisor | |
Roche/Genentech | Consultant or Advisor, Scientific Study or Trial | |
World Journal of Urology | Health Publishing | |
Urologic Oncology | Health Publishing | |
Bladder Cancer | Health Publishing | |
Robert Edward Brannigan, MD | The American Society for Reproductive Medicine (ASRM) | Leadership Position, Health Publishing |
The American Society for Reproductive Medicine | Leadership Position | |
The National Institutes of Health | Other | |
Rodney Henry Breau, MD | Nothing to disclose | |
Mark Patrick Cain, MD | Nothing to disclose | |
Toby C. Chai, MD | Nothing to disclose | |
Craig Vance Comiter, MD | zenflow | Scientific Study or Trial |
Avails medical | Consultant or Advisor | |
Neuspera | Consultant or Advisor | |
BE technologies | Scientific Study or Trial | |
Siamak Daneshmand, MD | Photocure | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial |
Taris | Consultant or Advisor | |
Pacific Edge | Consultant or Advisor | |
Ithaar H. Derweesh, MD | GlaxoSmithKline, Inc. | Scientific Study or Trial |
Pfizer, Inc. | Scientific Study or Trial | |
Scott E. Eggener, MD | NxThera | Consultant or Advisor |
Profound Medical | Consultant or Advisor | |
Genomic Health | Consultant or Advisor, Scientific Study or Trial | |
MDx Health | Consultant or Advisor, Meeting Participant or Lecturer | |
Opko Health | Consultant or Advisor, Scientific Study or Trial | |
Brian Howard Eisner, MD | Ravine Group | Owner, Product Development |
Gyrus/ACMI/Olympus | Consultant or Advisor | |
Boston Scientific | Consultant or Advisor | |
Bard | Consultant or Advisor | |
Retrophin | Consultant or Advisor | |
Allena | Consultant or Advisor | |
Kalera Medical | Consultant or Advisor | |
Howard B. Goldman, MD | allergan | Consultant or Advisor |
Medtronic | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
Cook | Scientific Study or Trial | |
Nuvectra | Consultant or Advisor | |
Axonics | Consultant or Advisor | |
NewUro | Consultant or Advisor | |
Jason C. Hedges, MD, PhD | Nothing to disclose | |
Wayne John G. Hellstrom, MD | Endo | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial |
Theralogix | Leadership Position | |
Coloplast | Consultant or Advisor, Meeting Participant or Lecturer | |
NIH | Leadership Position | |
New England Research Institutes, Inc | Other | |
Abbvie | Consultant or Advisor | |
Pfizer | Consultant or Advisor | |
Allergan | Consultant or Advisor | |
Boston Scientific | Consultant or Advisor | |
Virility | Consultant or Advisor | |
Ashish M. Kamat, MD | FKD | Scientific Study or Trial |
Photocure | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
Sanofi | Consultant or Advisor, Meeting Participant or Lecturer | |
Abbott Molecular | Consultant or Advisor | |
Theralase | Consultant or Advisor | |
Telesta Therapeutics Inc. (formerly Bioniche) | Consultant or Advisor | |
Heat Biologics | Consultant or Advisor, Scientific Study or Trial | |
Pacific Edge, Ltd | Meeting Participant or Lecturer | |
Merck | Consultant or Advisor, Scientific Study or Trial | |
Spectrum Pharmaceuticals | Consultant or Advisor | |
Oncogenix | Consultant or Advisor | |
Cepheid | Consultant or Advisor | |
Melissa Rae Kaufman, MD | Boston Scientific | Consultant or Advisor, Other |
Cook Myosite | Other | |
Simon Kim, MD | Nothing to disclose | |
Laurence H. Klotz, MD | Ferring | Consultant or Advisor, Scientific Study or Trial |
Amgen | Consultant or Advisor, Scientific Study or Trial | |
Astellas | Meeting Participant or Lecturer, Scientific Study or Trial | |
Medivation | Meeting Participant or Lecturer, Scientific Study or Trial | |
Abbvie | Meeting Participant or Lecturer, Scientific Study or Trial | |
Janssen | Meeting Participant or Lecturer, Scientific Study or Trial | |
Profound Medical | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
Badrinath R. Konety, MD, MBA | Photocure Inc | Scientific Study or Trial |
Genomic Health | Scientific Study or Trial | |
NxThera Inc | Consultant or Advisor | |
MDX Health | Consultant or Advisor | |
Genentech/Roche | Scientific Study or Trial | |
FKD Therapeutics | Scientific Study or Trial | |
Jaime Landman, MD | Cook Urological | Consultant or Advisor, Owner, Product Development |
Galil Medical | Consultant or Advisor | |
CONMED | Consultant or Advisor | |
Auris | Consultant or Advisor, Investment Interest | |
Allergan | Scientific Study or Trial | |
Gary Evan Lemack, MD | Allergan | Consultant or Advisor, Meeting Participant or Lecturer |
Roivant | Consultant or Advisor | |
Yair Lotan, MD | abbott | Scientific Study or Trial |
Cepheid | Consultant or Advisor, Scientific Study or Trial | |
Pacific Edge | Scientific Study or Trial | |
FKD | Scientific Study or Trial | |
MDxHealth | Consultant or Advisor, Scientific Study or Trial | |
biocancell | Scientific Study or Trial | |
Genomic Health | Scientific Study or Trial | |
GenomeDx Biosciences Inc | Scientific Study or Trial | |
photocure | Consultant or Advisor, Scientific Study or Trial | |
William Thomas Lowrance, MD | Myriad Genetics | Scientific Study or Trial |
Genome Dx | Scientific Study or Trial | |
Argos | Scientific Study or Trial | |
Stream Dx | Investment Interest | |
Kevin Thomas McVary, MD, FACS | Astellas | Scientific Study or Trial |
Lilly/ICOS | Consultant or Advisor, Scientific Study or Trial, Other | |
NIDDK | Scientific Study or Trial | |
AMS/Boston Scientific | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
NeoTract | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
Astellas | Scientific Study or Trial | |
Sophiris | Scientific Study or Trial | |
Merck | Consultant or Advisor | |
Maxwell V. Meng | AUA | Health Publishing |
Urologic Oncology (Journal) | Health Publishing | |
David Christopher Miller, MD,MPH | Blue Cross Blue Shield of Michigan | Other |
National Cancer Institute | Scientific Study or Trial | |
Nicole Lara Miller, MD | Boston Scientific Corporation | Consultant or Advisor, Meeting Participant or Lecturer |
Practical Reviews In Urology | Health Publishing | |
Joel Byron Nelson MD | Nothing to disclose | |
John Luther Phillips, MD | Nothing to disclose | |
Mrs.. Deborah F. Polly | Nothing to disclose | |
Sanoj Punnen, MD | Genome Dx | Meeting Participant or Lecturer |
OPKO Diagnostics | Scientific Study or Trial | |
Jay D. Raman, MD | American Kidney Stone Management | Investment Interest |
Pacific Edge Biotechnology | Consultant or Advisor, Scientific Study or Trial | |
Bradley Fields Schwartz ,MD | Cook Medical | Meeting Participant or Lecturer |
Ojas Shah, M.D. | Boston Scientific | Consultant or Advisor, Meeting Participant or Lecturer |
Elsevier | Health Publishing | |
American Urological Association | Meeting Participant or Lecturer, Other | |
Bristol Myers Squibb | Investment Interest | |
Retrophin | Consultant or Advisor | |
Applaud Medical | Consultant or Advisor | |
NJ Kidney Stone Center | Investment Interest | |
Glaxo Smith Kline | Investment Interest | |
Novartis | Investment Interest | |
Joseph A. Smith Jr.,MD | Nothing to disclose | |
Kevan A. Sternberg ,MD | The Journal of Urology | Leadership Position |
John T. Stoffel MD | Uroplasty | Scientific Study or Trial |
PCORI | Scientific Study or Trial | |
Journal of urology | Leadership Position | |
Department of Defense | Scientific Study or Trial | |
Ipsen | Scientific Study or Trial | |
Ramakrishna Venkatesh | Nothing to disclose | |
Julian Hsin-Cheng Wan MD | Allergan | Scientific Study or Trial |
Journal of Urology | Health Publishing |
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 24.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/ or Education Conflict of Interest Review Committee or its subgroup
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point- counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Evidence-based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
Off label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Release Date: May 2020.
Expiration Date: May 2023.
Copyright © 2020 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation